Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects.
AuthorJeng, Bennie H
Kirshner, Ziv Z
Mendez, Benjamin C
Wessel, Howard C
Brown, Larry R
Steed, David L
JournalTranslational Vision Science & Technology
PublisherAssociation for Research in Vision and Ophthalmology
MetadataShow full item record
AbstractObjective: An exploratory phase II, multicenter, open-label, clinical trial (NCT03687632) was conducted to evaluate the safety and effectiveness in treating persistent corneal epithelial defects (PEDs) with ST266, a proprietary novel multi-cytokine platform biologic solution secreted by cultured Amnion-derived Multipotent Progenitor (AMP) cells. Methods: Subjects with a PED were treated with ST266 eye drops 4 times daily for 28 days, then followed for 1 week. Safety was assessed by monitoring of adverse events (AEs) and serious adverse events (SAEs). Efficacy was assessed by measuring the area of the PED by slit lamp biomicroscopy. Tolerability of ST266, percentage of eyes with complete healing, reduction in area of the epithelial defect, and maintenance of a reduction in the area of the epithelial defect 7 days after treatment were recorded. Results: Thirteen patients were enrolled into the trial at one of eight sites. The first patient withdrew after 5 days. The remaining 12 patients with PEDs with median duration of 39 days (range = 12 to 393 days) completed treatment. Ten of the 12 eyes had been refractory to treatment with various conventional therapies prior to enrollment. After 28 days of treatment, there was a significant decrease in mean PED area compared with baseline (66.4% ± 35.3%, P = 0.001). At follow-up, 1 week after completion of treatment, on day 35, the PED area was further reduced by 78.8% ± 37.5% (P = 0.01) compared with baseline. During 28 days of treatment, 5 eyes (41.7%) had complete wound closure. There were no AEs of concern thought to be related to the drug, and no SAEs were noted. Conclusions: In this trial, we found ST266 eye drops might promote corneal epithelization, thereby reducing the PED area, including in refractory cases in a wide range of etiologies. ST266 was well-tolerated by most patients.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17813
- Topical insulin for refractory persistent corneal epithelial defects.
- Authors: Diaz-Valle D, Burgos-Blasco B, Gegundez-Fernandez JA, Garcia-Caride S, Puebla-Garcia V, Peña-Urbina P, Benitez-Del-Castillo JM
- Issue date: 2021 Sep
- Use of amnion-derived cellular cytokine solution for the treatment of gingivitis: A 2-week safety, dose-ranging, proof-of-principle randomized trial.
- Authors: Hasturk H, Steed D, Tosun E, Martins M, Floros C, Nguyen D, Stephens D, Cugini M, Starr J, Van Dyke TE
- Issue date: 2021 Sep
- Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects.
- Authors: Yamada N, Morishige N, Yanai R, Morita Y, Kimura K, Chikama T, Nomizu M, Sonoda KH, Nishida T
- Issue date: 2012 Dec
- Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea.
- Authors: Moon HS, Li L, Yoon HJ, Ji YS, Yoon KC
- Issue date: 2020 Apr 15
- RGC Neuroprotection Following Optic Nerve Trauma Mediated By Intranasal Delivery of Amnion Cell Secretome.
- Authors: Grinblat GA, Khan RS, Dine K, Wessel H, Brown L, Shindler KS
- Issue date: 2018 May 1